Tests angiotensin-(1-7) infusion in adults with obesity and insulin resistance
Tests whether an infusion of angiotensin-(1-7) affects insulin sensitivity in adults with obesity.
Plain-language title generated from the registry record
Registry title: Metabolic Effects of Angiotensin-(1-7)
Key facts
- Where
- Nashville, United StatesSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT02646475, who can take part
Where in United States
- Vanderbilt University Medical CenterNashville, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vanderbilt University
- Trial code
- NCT02646475
- Record updated
- 22 May 2026
- Original description
The overall purpose of this study is to learn more about the metabolic effects of angiotensin-(1-7) in the insulin resistant state associated with obesity. Pharmacologic approaches to increase angiotensin-(1-7) levels or its actions are currently in development for treatment of metabolic-related diseases such as obesity and type II diabetes, based on findings from animal studies. It is unclear if this peptide contributes to the regulation of metabolism in humans. The investigators will test if angiotensin-(1-7) infusion can improve insulin sensitivity measured by hyperinsulinemic-euglycemic clamp methods in individuals with obesity and insulin resistance. The investigators will also examine for changes in blood pressure and related hemodynamic and hormonal changes following angiotensin-(1-7) infusion.Read full original descriptionShow less
Metabolic Effects of Angiotensin-(1-7)
The overall purpose of this study is to learn more about the metabolic effects of angiotensin-(1-7) in the insulin resistant state associated with obesity. Pharmacologic approaches to increase angiotensin-(1-7) levels or its actions are currently in development for treatment of metabolic-related diseases such as obesity and type II diabetes, based on findings from animal studies. It is unclear if this peptide contributes to the regulation of metabolism in humans. The investigators will test if angiotensin-(1-7) infusion can improve insulin sensitivity measured by hyperinsulinemic-euglycemic clamp methods in individuals with obesity and insulin resistance. The investigators will also examine for changes in blood pressure and related hemodynamic and hormonal changes following angiotensin-(1-7) infusion.
Inclusion: Males and females of all races between 18 and 60 years of age; Obesity defined as body mass index between 30-40 kg/m2; Insulin resistance defined as homeostasis model assessment 2 insulin resistance (HOMA2-IR) score >2.2; Hypertension defined by two or more properly measured seated blood pressure readings >130/85 mmHg, or by use of anti-hypertensive medications. This blood pressure cutoff will allow us to include subjects with pre-hypertension; Able and willing to provide informed consent.
Exclusion: Previous allergic reaction to study medications; Cardiovascular disease other than hypertension such as myocardial infarction within 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy; Treatment with serotonin-norepinephrine reuptake inhibitors (SNRIs) or norepinephrine transporter (NET) inhibitors; Treatment with phosphodiesterase 5 inhibitors; Treatment with anticoagulants; Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days in 1 month); Treatment with any investigational drug in the 1 month preceding the study; Current smokers or history of heavy smoking (>2 packs/day); History of alcohol or drug abuse; History of serious cerebrovascular disease such as cerebral hemorrhage, stroke, or transient ischemic attack; History or presence of immunological or hematological disorders; Evidence of type I or type II diabetes (i.e. fasting glucose >126 mg/dl, use of anti-diabetic medications); Impaired hepatic function [aspartate amino transaminase (AST) and/or alanine amino transaminase (ALT) > 2.0 x upper limit of normal range]; Impaired renal function (serum creatinine >1.5 mg/dl); Anemia (hemoglobin <13.5 g/dl in males or <12.5 g/dl in females); Other factors which in the investigator's opinion would prevent the subject from completing the protocol (i.e., clinically significant abnormalities on clinical, mental examination or laboratory testing or inability to comply with protocol); Pregnancy or breast-feeding; Morbid obesity (BMI > 40 kg/m2); Inability to give, or withdraw, informed consent.